Johnson & Johnson Reports Three-Year Crohn’s Drug Results
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) reported new Phase 3 clinical trial results showing sustained remission in patients receiving its Crohn’s disease treatment Tremfya for three years, …
Johnson & Johnson Reports Three-Year Crohn’s Drug Results Read More